ArticleThe Lancet. Oncology2023

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.

Andrew J Cowan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.